
Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study
Keywords: مهارکننده های mTOR; mTOR inhibitors; Advanced non–small-cell lung carcinoma; Temsirolimus; Window of opportunity